Company Overview of Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. operates as a late-stage oncology focused pharmaceutical company. It offers entinostat, an oral histone deacetylase (HDAC) inhibitor that inhibits cancer-relevant HDAC enzymes, which contribute to epigenetic alterations driving cancer growth and drug tolerance. The company develops and commercializes products for lung and breast cancer, and solid tumors and hematologic malignancies in the United States and internationally. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
460 Totten Pond Road
Waltham, MA 02451
Founded in 2005
Key Executives for Syndax Pharmaceuticals, Inc.
Chief Executive Officer and Director
Co-Founder and Vice President of Translational Medicine
Compensation as of Fiscal Year 2012.
Syndax Pharmaceuticals, Inc. Key Developments
Syndax Pharmaceuticals, Inc. Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
May 14 13
Syndax Pharmaceuticals, Inc. announced the publication in the Journal of Clinical Oncology of positive results of a phase 2 randomized, double-blind, placebo-controlled study of the company's lead drug entinostat. The study showed that entinostat extended both progression-free survival and overall survival when added to exemestane in postmenopausal women with estrogen receptor-positive (ER+) breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor. The study evaluated entinostat in 130 postmenopausal women with advanced ER+ breast cancer, progressing on a nonsteroidal aromatase inhibitor. Patients were randomly assigned to 25 mg exemestane daily plus 5 mg entinostat once per week (64 patients), or exemestane plus placebo (66 patients). The primary end point was progression-free survival (PFS); blood was also collected in a subset of patients for evaluation of protein lysine acetylation as a biomarker of entinostat activity. Based on intent-to-treat analysis, patients treated with entinostat saw improved median PFS to 4.3 months, versus 2.3 months in patients treated with placebo (hazard ratio 0.73; 95% confidence interval, 0.50 to 1.07; one-sided P = 0.055; two-sided P = 0.11). Overall survival was an exploratory endpoint, and median survival improved to 28.1 months in entinostat-treated patients versus 19.8 months in placebo-treated (hazard ratio 0.59; 95% confidence interval, 0.36 to 0.97; P = 0.036). Fatigue and neutropenia were the most frequent grade 3/4 toxicities; treatment discontinuation because of adverse events was higher in the entinostat group versus the placebo group (11% versus 2%). Protein lysine hyperacetylation in the entinostat-treated biomarker subset was associated with prolonged progression-free survival.
Syndax Pharmaceuticals, Inc. Presents at 15th Annual Bio CEO & Investor Conference, Feb-11-2013 02:00 PM
Feb 8 13
Syndax Pharmaceuticals, Inc. Presents at 15th Annual Bio CEO & Investor Conference, Feb-11-2013 02:00 PM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, NY 10022, United States. Speakers: Arlene M. Morris, Chief Executive Officer and Director.
Syndax Pharmaceuticals, Inc. Presents at Boston Biotech Conference CEO New York Conference, Nov-01-2012 through Nov-02-2012
Oct 18 12
Syndax Pharmaceuticals, Inc. Presents at Boston Biotech Conference CEO New York Conference, Nov-01-2012 through Nov-02-2012. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Presentation Date & Speakers: Nov-01-2012, Arlene M. Morris, Chief Executive Officer and Director. Nov-02-2012, Arlene M. Morris, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|